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ABSTRACT 
To control gene expression, transcription factors (TFs) bind to DNA and recruit 
regulatory cofactors (COFs) that mediate diverse effects on chromatin, such as DNA and 
histone modifications. To better help understand TF and COF interactions, our lab has 
been developing the nuclear extract protein-binding microarray (nextPBM) approach that 
allows high-throughput characterization of COF recruitment to DNA. An extension of the 
nextPBM, the human TF array (hTF array), allows COF recruitment to be profiled to 
binding sites of hundreds of human TFs, providing a method to screen TF-COF 
complexes forming in cell nuclear extracts. DNA (cytosine-5)-methyltransferase 3 alpha 
(DNMT3A) and (cytosine-5)-DNA-methyltransferase 3 beta (DNMT3B), two isoforms 
of the methyltransferase DNMT3, are COFs that are known to be implicated in B-cell 
lymphoma. hTF experiments for DNMT3A recruitment in B-cell lymphoma cells 
revealed a number of interactions with known B-cell TFs. In this work, I have attempted 
to validate the interactions seen on the hTF array by testing TF interactions with both the 
native DNMT3A/B proteins and the central TF-interacting ATRX-DNMT3-DNMT3L 
(ADD) domains of DNMT3A/B through the use of an immunoprecipitation (IP) assay in 
RC B-cell lymphoma cells. I successfully cloned and purified the ADD domains of 
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DNMT3A and B as GST epitope-tagged constructs. As preliminary hTF experiments 
predicted interactions of DNMT3A with Interferon Regulatory Factor (IRF) proteins, I 
tested whether the DNMT3 ADD domains interacted with IRF3 present in B-cell 
lymphoma cell extracts, but was unable to identify an interaction. To examine whether 
native DNMT3A interacted with the IRF proteins, I performed a native IP using a 
DNMT3A native antibody. However, I was unable to confirm this interaction by native 
extract co-IP. Future work to validate DNMT3A/B-TF interactions, and TF-COF 
interactions identified by the hTF platform more generally, can help us understand at a 
molecular level what is facilitating transition between normal and cancerous states. 
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CHAPTER 1: Introduction 
 
1.1 Transcription Factors and Cofactors 
Transcription factors (TFs) bind to DNA and modulate the function of gene 
regulatory control elements, such as enhancers and promoters (Figure 1.1). Many TFs 
function by recruiting regulatory cofactors (COFs) to DNA sequences (Reiter et al., 
2017) (Figure 1.1). These recruited COFs mediate a diverse range of regulatory processes 
that impact gene expression, such as ATP-dependent chromatin remodeling, histone 
modification (i.e., acetylation and methylation), and DNA modification (e.g., 
methylation). The TF-COF complexes functioning in a cell provide the means to target 
these COF activities to specific genomic loci to target specific genes. Therefore, the 
interactions of TF with COFs is critical to understanding the mechanisms by which gene 
expression is controlled in normal and pathogenic settings. The field has primarily been 
focused on mapping TF-DNA interactions and how these interactions contribute to gene 
expression. However, it is also important to understand how COFs are recruited to certain 
loci in the genome, and development of technical approaches to study TF-COF 
interactions will be important for mapping TF-COF complexes in a cell-specific manner 
(Keilwagen et al., 2019). 
1.2 DNA Methylation in Relation to DNA methyltransferases 
DNA methyltransferases are a class of COFs that methylate DNA at cytosine 
residues in mammalian cells. Methylation of DNA at cytosine residues in mammalian 
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cells is a heritable, epigenetic modification that is needed for correct regulation of gene 
expression, genomic imprinting and development (Turek-Plewa and Jagodziński, 2005) 
(Figure 1.2). There are three human DNA methyltransferases (DNMTs): DNMT1, 
DNMT3A, and DNMT3B (Lyko, 2017). DNMT1, DNMT3A and DNMT3B methylate 
the C-5 carbon of cytosines. DNMT1 is constitutively expressed in proliferating cells and 
functions as a maintenance methyltransferase, making sure the newly synthesized strand 
is properly methylated during replication. DNMT1 is comprised of around 1600 amino 
acids, with an N-terminal regulatory region covering two thirds of the sequence, a highly 
conserved (GK)n repeat and a C-terminal MTase domain, a foci-targeting sequence 
(RFTS) domain, a CXXC zinc finger domain and a pair of bromo-adjacent-homology 
(BAH) domains (Ren, Gao, and Song, 2018) (Figure 1.3). DNMT3A and DNMT3B 
function as de novo methyltransferases that methylate previously unmethylated regions of 
DNA. DNMT3A and DNMT3B are structurally similar and both have a N-terminal 
region which consists of a PWWP domain and ADD domain (Chen and Chan, 2014). The 
PWWP domain is needed for DNA binding and also interacts with the H3K36m3 mark. 
The PHD-like ADD domain is involved in protein-protein interactions and interacts with 
the unmethylated H3K4 mark. DNMT3A and DNMT3B both have a MTase domain in 
the C-terminal region which catalytically controls the mechanism of de novo methylation 
(Figure 1.3). DNMT1, DNMT3A and DNMT3B combine to form a protein complex that 
interacts with histone deacetylases (HDAC1, HDAC2, Sin3A), transcriptional repressor 
proteins (RB, TAZ-1) and heterochromatin proteins (HP1, SUV39H1), to maintain levels 
of DNA methylation and allow gene silencing (Kim et al., 2002).  
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Improper DNA methylation contributes to diseased states such as cancer (Yang et 
al., 2015). Hypermethylation of promoter CpG islands within tumor suppressor genes 
correlates with gene silencing and the development of cancer. However, hypomethylation 
of genomic DNA can also contribute to cancer, demonstrating that dysregulation of 
DNMTs can have severe consequences on cell integrity. DNMT1, DNMT3A and 
DNMT3B are over-expressed in many cancers, including acute and chronic myelogenous 
leukemias, in addition to colon, breast and stomach carcinomas (Mizuno et al., 2001). 
Understanding the basis of DNMT expression and differential recruitment to DNA is 
important in clarifying drivers of cancer.   
The two de novo DNMTs, DNMT3A and DNMT3B, that can be recruited to 
DNA are known to interact with a diverse array of TFs. Structural studies have shown 
that TFs tend to bind to the ADD domain of DNMT3A and DNMT3B rather than the 
PWWP or catalytic domain. In a study by Hervouet et al. (2009), 69 transcription factors 
were found to interact with DNMT3A and 52 transcription factors interacted with 
DNMT3B (Figure 1.4). In addition, PU.1, an E26 transformation-specific (ETS) TF and a 
hematopoietic regulator essential for the development of myeloid and B-cell lineages, 
interacts with the ADD domain of both DNMT3A and DNMT3B in mouse fibroblasts 
(Suzuki, 2006). Also, p53, a known tumor suppressor, interacts with the ADD domain of 
DNMT3A (Wang et al., 2005). It is concluded that these interactions play crucial roles in 
the epigenetic regulation of mammalian gene expression. Determining the TFs that can 
interact with DNMT3A and DNMT3B in a cell specific manner will be critical to 
delineating how methylation states are established and dysregulated.  
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1.3 Diffuse Large B Cell Lymphoma and Epigenetic Regulation 
DNMTs have been widely investigated in certain cancer types such as leukemia 
and carcinoma. However, the role of DNMT3A and DNMT3B in diffuse large B-Cell 
lymphoma (DLBCL) has not been investigated thoroughly, especially the mechanisms 
driving aberrant methylation. Epigenetic alterations in lymphomas are predominantly 
driven by mutations in chromatin-modifying enzymes that lead to changes in promoter 
accessibility for TFs or protein complexes involved in DNA methylation. Affected DNA 
methylation patterns ultimately cause dysregulation of tumor suppressor genes, leading to 
sustained proliferation and tumor formation or creating an oncogenic form of a normal 
gene (Di Pietro et al., 2018). Diffuse large B-cell lymphoma (DLBCL) is the most 
common type of non-Hodgkin lymphoma worldwide (Pham et al., 2015). In the USA, 
DLBCL represents approximately 30% of all new lymphoma cases per year and is the 
fifth most common cancer. DNA methyltransferases have been shown to be implicated in 
B cell non-Hodgkin lymphomas (B-NHLs) which comprise a heterogeneous group of 
tumors arising from different stages of mature B lymphocytes (De Paepe and De Wolf-
Peeters, 2007). Also, a study by Reddy et al. (2017) showed genes that were dysregulated 
in B cell lymphomas including DNMT3A. Most of the dysregulated genes in DNMT3A 
were due to missense mutations.  
Thesis Rationale:  
To characterize TF-COF complexes functioning in cells, our lab has been 
developing a protein-binding microarray (PBM)-based approach, called CoRec (Cofactor 
Recruitment), to profile TF-COF complexes from cell nuclear extracts. PBMs are double-
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stranded DNA microarrays that allow in vitro measurement of protein binding to tens of 
thousands of unique DNA sequences (Berger and Bulyk, 2009). PBMs have been used to 
study the DNA binding of purified proteins and protein complexes. More recently, to 
characterize binding of protein and protein complexes in a more native context, our lab 
has developed the nextPBM (nuclear extract protein-binding microarray) approach where 
nuclear extracts are used instead of purified protein samples (Mohaghegh et al., 2019). 
The CoRec approach builds upon this nextPBM approach of using nuclear extracts but 
focuses on the recruitment of COFs to DNA probes, instead of the binding of TFs. By 
monitoring the DNA sequence specificity of COF recruitment, we can infer the identity 
of the TF that is recruiting a COF to a particular DNA sequence, allowing us to profile 
many TF-COF complexes in parallel. We have recently developed a microarray design, 
called the hTF (human transcription factor) array, that allows us to profile COF 
recruitment to ~400 TF binding sequences and thereby profile many TF-COF complexes 
functioning in cells.  
In an on-going project in the lab, we are using the CoRec method with the hTF 
microarray platform to analyze TF-COF complexes in DLBCL lymphomas. CoRec 
experiments profiling the recruitment of DNMT3A in RC lymphoma cells identified 
interactions with ETS and IRF class TFs (Figures 1.5 and 1.6). These experiments 
indicate that DNMT3A is interacting with TFs of the ETS and IRF classes; however, they 
do not indicate which part of the DNMT3A protein is involved in these TF interactions. 
For this thesis, I aimed to both validate the DNMT3A-TF interactions through 
immunoprecipitation using GST-tagged purified DNMT3 ADD domains to investigate 
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whether these DNMT3A-TF interactions were mediated through the ADD domain, 
previously shown to interact with IRF and ETS family proteins.  
 
 
Figure 1.1 Transcription factors bind to regulatory regions to regulate gene 
expression. Enhancers contain DNA binding motifs that are specific to certain 
transcription factors (TFs). These TFs recognize and bind those DNA binding motifs. 
Subsequent to binding to enhancers, TFs can recruit cofactors (COFs), which can 
enhance or repress transcription. Transcription factor (TF); cofactor (COF); Polymerase 





Figure 1.2 The characteristics of DNMTs in mammalian cells. DNMTs methylate the 
C-5 carbon of cytosines. This alters the patterns of gene regulation and protein expression 
which ultimately alters chromosome stability, embryo development, cell differentiation, 
and tumorigenesis (From Zhang et al., 2020). 
 
 
Figure 1.3 Domain Structures of DNMT1, DNMT3A and DNMT3B. Mapped out 
domain structure of human DNA methyltransferases: DNMT1, DNMT3A and DNMT3B. 
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Numbers indicate amino acids. ADD domain (underlined) was used for cloning. 




Figure 1.4 Transcription factor interactions with DNMT3 and its isoforms. DNMT-
TF interactions were profiled on a transcriptional factor array. Transcription factors can 







Figure 1.5 Recruitment preferences of DNMT3A to TF binding sites. hTF 
experiments profiled recruitment of DNMT3A to DNA probes representing consensus 
binding sites for TFs and all single-nucleotide variants (SNVs). DNMT3A recruitment is 
quantified using a z-score reflecting binding above random background. Shown are the z-
scores distributions of DNMT3A recruitment to consensus/SNV probe sets representing 
each indicated TF (listed on x axis). Z-scores indicate a TF’s recruitment strength for 




Figure 1.6 Cofactor recruitment motifs showing DNMT3A interactions with ELK1 
and IRF3. A. The cofactor DNMT3A interacts with a generic TF with a known 
transcription factor binding site (TFBS). hTF-determined COF recruitment to consensus 
TF binding sites and single-nucleotide variant probes can be used to construct a COF 
recruitment motif. B. Shown is a COF recruitment motif determined for the ELK1 probe 
set, and the corresponding DNA-binding motifs for this TF. C. Shown is a COF 
recruitment motif determined for the IRF3 probe set, and the corresponding DNA-
binding motifs for this TF. Motif correspondence indicates that the DNMT3A COF was 
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likely recruited by a TF exhibiting similar DNA binding specificity. Here DNMT3A is 
shown to be recruited to the ELK1 and IRF3 sites with the corresponding DNA sequence 




CHAPTER 2: Materials and Methods 
 
2.1 Cell Culture 
2.1.1 Cell Lines 
RC double-hit B-cell lymphoma cells (ATCC® CRL-3382™) were grown in a 
growth medium composed of RPMI-1640 Medium (Invitrogen) supplemented with 10% 
heat-inactivated FBS (Gibco). Cells were kept in a 37°C incubator under 5% CO2. Cells 
were maintained at a density of 500,000 cells/mL. 
2.1.2 Nuclear Extraction of RC Cells 
To harvest nuclear extracts from RC cells, the RC cells were transferred to a 50 
mL conical tube and spun down in a centrifuge at 3000 RPM for 5 minutes at 4°C. The 
media was aspirated off and the cells were washed with 1X phosphate-buffered saline 
(PBS) and 0.1 mM protease inhibitor (Sigma Aldrich). After pipetting up and down 
several times, the cells were centrifuged at 3000 RPM for 5 minutes at 4°C. Once the 
cells were pelleted, the supernatant was aspirated off. The pellet was resuspended in 1 
mL of Buffer A (10 mM HEPES, pH 7.9, 1.5 mM MgCl, 10 mM KCl, 0.1 mM protease 
inhibitor, phosphatase inhibitor [Santa Cruz Biotechnology], 0.5 mM DTT) and 
incubated for 10 minutes on ice to lyse the plasma membrane. After the 10-minute 
incubation, 20 μL of 0.1% Igepal detergent was added to the cell and Buffer A mixture 
and vortexed for 10 seconds. To separate the cytosolic fraction from the isolated nuclei, 
the sample was centrifuged at 3000 RPM for 5 minutes at 4°C. The cytosolic fraction was 
collected into a separate microcentrifuge tube. To wash the pelleted nuclei, 100 μL of 
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cold Buffer A was added to the wall of the tube with the isolated nuclei. The pellet was 
centrifuged at 3000 RPM for 1 minute. This step was repeated twice. The pelleted nuclei 
were then resuspended in 100 μL of Buffer C (20 mM HEPES, pH 7.9, 25% glycerol, 1.5 
mM MgCl, 0.2 mM EDTA, 0.1 mM protease inhibitor, phosphatase inhibitor, 0.5 mM 
DTT, and 420 mM NaCl) and then vortexed for 30 seconds. The nuclei were incubated in 
100 μL of Buffer C while mixing at 4°C in a hula mixer with the following settings: 
Orbital-25 RPM/off, Reciprocal-90°/30, Vibro-5°/5. To separate the nuclear extract from 
the insoluble nuclear proteins, the mixture was centrifuged at 14,000 RPM for 20 minutes 
at 4°C. Afterwards, the isolated nuclear extract was quantified using a NanoDrop 
Spectrophotometer by adjusting the setting to protein and then BSA. The concentration of 
the nuclear extract usually measured ranges from 9.0 mg/mL to 15 mg/mL. The nuclear 
extract was flash frozen using liquid nitrogen and stored at -80°C until further use.  
2.2 Recombinant DNA Techniques 
2.2.1 DNMT3A ADD Domain, DNMT3B ADD Domain and GST Control Cloning  
The gene sequences for the ADD domains of DNMT3A and DNMT3B were 
found in the literature (Ren et al., 2018). They were optimized using the Benchling IDT 
Codon Optimizer (Figure 2.2). The Gateway Cloning Manual was followed for the 
cloning procedure. AttB sites were added to each end of the domain sequence (Table 
2.1). The optimized sequences were ordered from Quintara, and cloned into pDONR221, 
a bacterial donor vector, using DH5α E.coli. A BP reaction was performed to insert the 
gene sequence that encodes for the ADD domains of DNMT3A and DNMT3B into the 
pDONR221 plasmid. This reaction included 1 μL of pDONR221 donor vector, 100 ng of 
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DNMT3A/B ADD domain insert, 2 μL of BP clonase enzyme, and 8 μL of nuclease free 
water. Afterwards, 5 μL of the BP reaction was added to 40 µL of DH5α E.coli cells and 
the mixture was incubated on ice for 10 minutes. The cells were then heat-shocked for 30 
seconds in a 42°C water bath to permeabilize the cell membrane and allow the 
introduction of plasmid DNA into the cells. 300 μL of Luria-Bertani broth (LB) was 
added to the transformed bacteria and this was incubated on ice for 2 minutes. The 
transformed bacteria were then allowed to recover for 1 hour in a 37°C shaking 
incubator. Transformed bacteria were plated on LB agar plates containing the antibiotic 
kanamycin (1000X) to select for clones with the transformed plasmid. The plates were 
incubated overnight at 37°C. After the pDONR221 plasmid DNA was isolated by a mini-
prep (described in 2.2.2) and the DNMT3A/B ADD domain insert was confirmed by a 
restriction enzyme digest, the LR reaction was performed in order to incorporate the 
ADD domain sequence from the pDONR221 plasmid to the pDEST15 plasmid, which is 
specialized for protein expression with a glutathione S-transferase (GST) tag. 1 μL of 
pDEST15 destination vector, 100 ng of insert (pDONR221 with insert), 2 μL of LR 
clonase enzyme, and 8 μL of nuclease free water. After the LR reaction, the same steps 
are repeated as after the BP reaction, but with the antibiotic carbenicillin instead. For a 
control in the immunoprecipitation assay, a construct that is only GST was desired. A 
construct only containing GST was obtained as described in 2.2.3. This fragment was 
used as the insert for the BP reaction in the same steps described previously. For the LR 
reaction, pDEST14 rather than pDEST15 was used as the destination vector for the GST 
control. This is because pDEST14 has no GST tag so the product after the LR reaction 
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will only produce GST. After the LR reaction, the same steps are repeated as after the BP 
reaction, but with the antibiotic carbenicillin (1000X) instead. 
2.2.2 Mini-Prep DNA Preparations  
A mini-prep procedure to isolate and purify DNA needed to be performed after 
the BP reaction and after the LR reaction. DNA was isolated using a QIAprep Spin 
Miniprep Kit (Qiagen). First, one colony was picked per plate for the pDONR221 
plasmid containing either the DNMT3A ADD domain insert, DNMT3B ADD domain 
insert, or GST insert. The picked colony was inoculated in 3 mL of LB with either the 
antibiotic kanamycin or carbenicillin and was allowed to grow overnight in a 37°C 
shaking incubator. The following day, 1.5 mL of the 3 mL overnight culture was 
transferred to a 2 mL microcentrifuge tube and centrifuged at 8000 RPM at room 
temperature for 3 minutes. This step was repeated a second time. The supernatant was 
decanted and the pellet was resuspended in 250 μL of Buffer P1 (50 mM Tris-Cl, pH 8.0, 
10 mM EDTA, 100 ug/mL RNase A). 250 μL of Buffer P2 was added to the mixture and 
inverted six times. The DNA was precipitated by adding 350 μL of Buffer N3 (3.0 M 
potassium acetate, pH 5.5). The samples were centrifuged at 13,000 RPM for 10 minutes. 
The supernatant was transferred to a spin column and the pellet was washed with 750 μL 
of Buffer PE and then centrifuged at 13,000 RPM for 1 minute. The supernatant was 
decanted and the pellets were centrifuged at 13,000 RPM for 1 minute. 50 μL of nuclease 
free water was added directly to the column, incubated for 1 minute at RT, and then 
centrifuged at 13,000 RPM for 1 minute to elute purified DNA. To ensure that the final 
constructs of the DNMT3A/B ADD domain and GST control were the desired sequence, 
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they were sent for DNA sequencing performed by Eton Biosciences. 8 μL of 150 ng/μL 
purified plasmid DNA was combined with primers supplied by Eton (Table 1). 
2.2.3 Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction was performed for amplification of glutathione S-
transferase out of pDEST15 for use as a negative control for the protein pulldown. A 50 
μL reaction was run using 2.5 μL each of the reverse and forward primer (Table 1), 2 μL 
of the pDEST15 plasmid, 25 μL of Q5 Master Mix (NEB), and 18 μL of nuclease free 
water. Each reaction mixture was gently mixed and centrifuged before placing it in the 
thermocycler. The PCR program that was used was an initial denaturation step for 30 
seconds at 98°C, then 35 cycles of 98°C for 10 seconds, 65°C for 30 seconds, 72°C for 1 
minute, and a final extension for 2 minutes at 72°C. The PCR reactions were stored at -
20°C. To verify that the PCR reaction amplified the GST fragment of the pDEST15 
plasmid, the amplified DNA was run on a 1.2% agarose gel (0.6 g of agarose and 50 mL 
of TAE buffer [242 g of tris base, 57.1 mL of glacial acetic acid, 100 mL of 0.5 M EDTA 
(pH 8.0), 842.9 mL dH2O]. Since the GST fragment was amplified, it could be used as 
the insert DNA in the BP reaction.  
2.3 Protein Expression Techniques 
2.3.1 DNMT3A/DNMT3B ADD Domain and GST Control Protein Expression 
The pDEST15 plasmid consisting of the DNMT3A/B ADD domain and the 
pDEST15 plasmid consisting of GST were transformed into BL21(DE3) E.coli cells for 
protein expression. One colony was chosen and inoculated overnight in 5 mL of LB broth 
and the antibiotic carbenicillin. The next day, the starter culture was added to a larger 400 
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mL culture (supplemented with 400 μL of carbenicillin (1000X), 50 mM zinc sulfate 
heptahydrate, and 5 g/L ammonium sulfate). The cultures were then grown at 37°C in a 
shaker for four hours or until an optical density of 0.3 was reached at a wavelength of 595 
nm. Next, the cultures were grown in a room temperature shaker until an OD595 of 0.6 
was reached. Once the cultures had reached an OD595 of 0.6, induction was performed 
by adding 0.5 mM IPTG into the culture (200 μL of 1 M stock per 400 mL). The 
induction was allowed to go for three hours, and 1 mL samples were taken each hour to 
check for protein expression. After three hours, the induced cultures were transferred to 
50 mL conical tubes and spun 4000 RPM for 10 minutes at 4°C in a centrifuge. The cell 
pellets were washed with cold 1X PBS, and snap frozen at -80°C. 
2.3.2 Protein Purification 
For protein purification, the DNMT3A/B ADD domain and GST control cell 
pellets were thawed and resuspended in lysis buffer (1X PBS, 0.02% Triton X-100, 2 
mM DTT, 1 mM PMSF, 5 μM zinc sulfate), and lysed using a microfluidizer. The lysed 
pellets were combined with 400 μL of glutathione magnetic beads (GenScript) and 
allowed to incubate at 4°C overnight on a rotator. . All of the peptides were eluted using 
the elution buffer (50 mM Tris-Base, 10 mM reduced glutathione, pH to 8.0 using 
concentrated HCl). The eluted protein samples were quantified using a NanoDrop 
Spectrophotometer. The concentration of purified protein usually ranged from 1-2 
mg/mL. The eluted proteins were run on a SDS-PAGE gel and the gel was stained with 
SimplyBlue SafeStain (Thermofisher) to see if the protein was expressed and of the 
expected size. A western blot was also run to confirm the identity and purity of protein by 
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using an antibody specific to GST (table 2.2). 
2.4 Immunoprecipitation Techniques 
2.4.1 GST-Tagged DNMT3A and DNMT3B ADD Domain Pulldown 
50 μL of Sigma Aldrich glutathione agarose magnetic beads (Sigma Aldrich) 
were washed with 250 μL 1X HBS (HEPES-buffered saline) (20 mM HEPES, pH 7.9, 
137 mM NaCl, 1.5 mM MgCl2) in a 2 mL flat bottom Eppendorf tube to facilitate 
mixing. The Eppendorf tube was placed on the magnet for 1 minute to separate the beads 
from the 1X HBS. Once the liquid was clear, the supernatant was removed by placing the 
tip of the pipette against the wall of the Eppendorf tube that is opposite the side touching 
the magnet. This was repeated two times. Then, 100 μL of 1X HBS and 20 μL of GST 
tagged protein (DNMT3A ADD domain, DNMT3B ADD domain, or GST) were added 
to the Eppendorf tube with the 50 μL of beads. This mixture was incubated in a hula 
mixer for 30 minutes at 4°C with the following settings: Orbital-40 RPM/4, Reciprocal-
OFF, Vibro-OFF. These settings were used for the remainder of the assay. After this 
incubation, the Eppendorf tube was placed on the magnet and the supernatant was 
aspirated off using a pipette. The beads were washed with 250 μL of wash buffer (sterile 
water, 20 mM HEPES, 0.05% Tween-20). This step was repeated two times. A 100 mM 
salt concentration in nuclear extracts is conducive to see TF-COF interactions (need to 
find reference). Therefore, the volume of nuclear extract was added so that the final NaCl 
concentration was 100 mM. The binding buffer consisted of 0.3% milk in water, sterile 
water, 20 mM HEPES pH 7.9, 0.02% Triton X-100, 1 mM DTT, 0.2 mg/mL BSA, 1.11 
mM MgCl2. The buffer/extract mixture was added to the Eppendorf tube with the beads 
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and was allowed to mix overnight in a hula mixer at 4°C with the following settings: 
Orbital-40 RPM/4, Reciprocal-OFF, Vibro-OFF. After this incubation, the eppendorf 
tube with the beads was placed on the magnet and the supernatant was aspirated off using 
a pipette. The beads were washed with 250 μL of wash buffer for 30 seconds using the 
hula mixer. This step was repeated two times. The washes were saved to check if the 
protein of interest that is being probed for was in the wash lane instead of the elution 
lane. 40 μL of Elution Buffer (50 mM tris-base, 10 mM reduced glutathione, pH to 8.0 
using concentrated HCl) was added to the Eppendorf tube and was allowed to incubate 
for 10 minutes at 4°C with the hula mixer. The supernatant was removed and 8 μL of 4X 
Laemmli sample buffer and 2 μL of 10X BME were added to constitute a final volume of 
50 μL. The mixture was denatured by heating it on a heating block at 95°C for 5 minutes. 
The eluted proteins were run on an SDS-PAGE gel.  
2.4.2 Native DNMT3A Pulldown  
50 μL of Protein G magnetic beads (Invitrogen) were washed with 250 μL of 1X 
HBS in a 2 mL flat bottom Eppendorf tube to facilitate mixing. The Eppendorf tube was 
placed on the magnet for 1 minute to separate the beads from the 1X HBS. Once the 
supernatant was completely clear and the beads were fully attached to the side of the 
wall, the supernatant was removed by placing the pipette tip against the wall of the 
Eppendorf tube that is opposite the side touching the magnet. This was repeated two 
times. Then, 12 μg of either DNMT3A antibody or control mouse IgG antibody was 
diluted in 200 μL of 1X HBS and then added to the Eppendorf tube with the 50 μL of 
beads. This mixture was incubated in a hula mixer for 10 minutes at room temperature 
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with the following settings: Orbital-40 RPM/4, Reciprocal-OFF, Vibro-OFF. These 
settings were used for the remainder of the assay. After this incubation, the Eppendorf 
tube with the beads was placed on the magnet and the supernatant was aspirated off using 
a pipette. The beads were washed with 200 μL of wash buffer (same reagents used in 
2.4.1) and the supernatant was discarded. A 100 mM salt concentration in nuclear 
extracts is conducive to see TF-COF interactions. Therefore, the volume of nuclear 
extract was added so that the final NaCl concentration was 100 mM. The binding buffer 
consisted of the same reagents as in the GST pulldown except the concentration of BSA 
used was reduced to 0.1 mg/mL. The buffer/extract mixture was added to the Eppendorf 
tube with the beads and was let run overnight in a hula mixer at 4°C. After this 
incubation, the Eppendorf tube with the beads was placed on the magnet and the 
supernatant was aspirated off using a pipette. The beads were washed with 200 μL of 
wash buffer for 2 minutes using the hula mixer. This step was repeated two times. The 
washes volumes were saved to run on the SDS-PAGE gel to determine whether or not the 
protein of interest was being lost in the wash steps. 40 μL of elution buffer (10 μL of 4X 
Laemmli sample buffer, 4 μL of 10X BME, 26 μL of dH2O) was added to the Eppendorf 
tube containing the protein and beads and was allowed to incubate for 10 minutes on a 
heating block at 95°C. The eluate was removed and run on a SDS-PAGE gel.  
2.5 Western Blotting 
2.5.1 Western Blot on Nuclear Extracts and Pulldown Fractions 
The GST-tagged proteins, nuclear extract proteins, and proteins eluted in the 
pulldown assays were all analyzed by electrophoresis run on SDS denaturing 10-well 4-
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20% Mini-Protean TGX gels (Bio-Rad). Proteins were denatured in 10 μL of 4X 
Laemmli sample buffer (Bio-Rad) and 4 μL of 10X BME at 95°C each for 5 minutes in a 
final volume of 40 μL. Precision Plus Dual Color Pre-Stained Protein Standard (Bio-Rad) 
was also loaded onto the gels. Gels were electrophoresed until the blue dye front reached 
the bottom of the gel. Proteins were transferred onto a nitrocellulose membrane (Bio-
Rad) for 16 hours at 170 mA. The membrane was rinsed with 50 mL of deionized water 
(dH2O) and then incubated in 10 mL of blocking buffer (1X TBS pH 7.5 [6.05 g of Tris 
and 8.76 g of NaCl in 800 mL of sterile water]) for 1 hour at room temperature. The 
membrane was rinsed twice for 1 minute and 30 seconds in TBS-T (TBS pH 7.5 with 
0.1% Tween-20). Next, membranes were incubated with primary antibody diluted in 1X 
tris buffered saline (TBS) for 24 hours at 4°C on an orbital shaker (see Table 2.2 for 
primary antibodies and dilutions used). After that, the membrane was rinsed twice for 1 
minute and 30 seconds in TBS-T and then incubated for 1 hour at room temperature in 
horseradish peroxidase conjugated secondary antibody at a dilution according to Table 
2.2. Next, the membrane was rinsed twice for 1 minute and 30 seconds in TBS-T. 
Membranes were incubated in Supersignal west chemiluminescent substrate for 10 
seconds (Thermo Scientific). Western blot membranes were imaged using the Azure 




Table 2.1 Oligonucleotide table. 











DNMT3A Reverse Primer 5’-GATCCCGGGTCGAATCAA-3’ DNA sequencing 
DNMT3B Reverse Primer 5’-GATCCCGGGTCGAATCAA-3’ DNA sequencing 
GST Control Forward 
Primer 
5’-GGG GAC AAG TTT GTA CAA 
AAA AGC AGG CTT AAT GTC 
CCC TAT ACT AGG TTATTG GAA 
AAT TAA GG-3’ 
PCR 
GST Control Reverse 
Primer 
5’-GGG GAC CAC TTT GTA CAA 
GAA AGC TGG GTT TTT TGG 






Table 2.2 Western blot antibody table. 
Antibody  Catalog Number Dilution Used Application 
GST Sc-138  1:250 Western Blot 
RBBP5 A300-109A 1:5000 Western Blot 
DNMT3A sc-365769 1:100 Western Blot 
ELK1 sc-365876 1:100 Western Blot 
IRF3 sc-9082 1:1000 Western Blot 
IRF7 sc-9083X 1:1000 Western Blot 
HRP conjugated Goat anti-
Rabbit IgG A-11034 1:5000 Western Blot 
HRP conjugated Goat anti-
Mouse IgG A-11029 1:5000 Western Blot 
 
 
Table 2.3 Immunoprecipitation antibody table. 
Antibody Catalog Number Quantity (μg) used  Application 
DNMT3A sc-365769 12 Immunoprecipitation  
Mouse IgG sc-2025 12 Immunoprecipitation  











Figure 2.1 Gateway cloning method. The Gateway cloning method was used to 
generate an N-terminal GST-tagged peptide. A. The ADD domain of both DNMT3A and 
DNMT3B is cloned into pDONR221. The pDONR221 plasmid is then transformed into 
DH5α E. coli. B. The pDONR221 plasmid with the ADD domain insert was cloned into a 
pDEST15 plasmid. The pDEST15 plasmid is then transformed into DH5α E. coli C. The 





Figure 2.2 DNMT3A and DNMT3B codon optimized sequences. The ADD domain 
sequences of DNMT3A and DNMT3B were found in the literature (Ren et al., 2018) and 
codon optimized using Benchling. Arrows indicate attB1 and attB2 sites that were added 
onto the ends of the ADD domain sequence of DNMT3A and DNMT3B in order to use 




Chapter 3: Results  
 
3.1 Generation of the GST-tagged DNMT3A and DNMT3B ADD Domain to Use in 
the Immunoprecipitation Assay 
3.1.1 DNMT3A and DNMT3B ADD Domain Cloning 
To generate GST-tagged DNMT3A/B ADD domain proteins to be used in 
immunoprecipitation experiments, I cloned both ADD domains into a bacterial 
expression vector. DNA cloning was performed using the Gateway Cloning system 
(Figure 2.1). The DNA sequences of the ADD domains were ordered as linear, double-
stranded DNA constructs and were initially cloned into the donor pDONR221 plasmid. A 
restriction enzyme digest was run to ensure that the ADD domain was successfully 
cloned into the donor vector (Figure 3.1). pDONR221 was run as a control and was the 
expected size of 4761 bp. (Figure 3.1, lane 2). Both plasmids for the DNMT3A and 
DNMT3B were the expected size of 2966 bp and 2948 bp, respectively (Figure 3.1, lane 
3, 6). To further test that the inserts were correctly cloned, a sequential digest of the 
pDONR221 vectors containing the DNMT3A ADD domain inserts was performed using 
the enzymes EcoRV and ApaI. There were two expected bands of sizes 2330 bp and 636 
bp demonstrating that the cloned insert was the correct size (Figure 3.1, lane 5). A 
sequential digest using the enzymes EcoRV and ApaI was performed for the DNMT3B 
ADD domain clone, and there were two expected bands of sizes 2323 bp and 625 bp, 
demonstrating that the insert was the correct length (Figure 3.1, lane 8). The ADD 
domain constructs were then shuttled from the pDONR221 plasmid into the bacterial 
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expression plasmid pDEST15 using the Gateway transfer systems. The pDEST15 
expression vector also contains the N-terminal GST tag that will result in a tagged protein 
when expressed. The resulting pDEST15 vectors were sequenced and it was determined 
that the entry clones had been generated for the ADD domains. 
3.1.2 DNMT3A and DNMT3B ADD Domain Expression and Purification 
 To express the DNMT3A and DNMT3B ADD domains as GST-tagged proteins, 
the pDEST15 plasmid was transformed into BL21(DE3) cells and the cells were induced 
with IPTG. The GST-tagged ADD domains were purified using glutathione-agarose 
beads (Methods). To confirm the identity and purity of DNMT3A and DNMT3B, the 
purified samples were run on an SDS-PAGE gel and examined by a western blot and by 
Ponceau-stain gel (Figure 3.2). Both the western blot and Ponceau gel show that the 
purified samples were of the expected sizes of 43.6 kDa and 42.9 kDa for DNMT3A and 
DNMT3B, respectively (Figure 3.2, lane 1, 2). A GST control fragment (cloning 
described below) was expressed and purified in the same manner. The reason that two 
bands were seen in the western blot is due to the fact that the GST tag and connecting 
protein can detach under SDS conditions.  
3.2 Generation of the GST Fragment as the Negative Control to Use in the 
Immunoprecipitation Assay 
3.2.1 Cloning a GST Negative-Control Construct 
In immunoprecipitation pulldown assays, a negative control is needed to measure 
the background binding to ensure that any interaction between the GST-tagged ADD 
domain of DNMT3A is a real interaction and not a result of binding to the GST tag. GST 
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is a proper negative control to use in the pulldown assay because it is the tag that is 
attached to the DNMT3A ADD domain. A GST DNA fragment was generated by PCR 
with primers specific to the GST portion of the pDEST15 plasmid. To confirm that the 
primers were specific to GST and the PCR reaction successfully amplified GST, an 
agarose gel was run (Figure 3.3). The observed band for GST was the expected size of 
654 bp (Figure 3.3, lane 3). There was a faint band larger than the desired 654 bp 
fragment. That was likely a smear due to the high voltage the gel was run at. The PCR 
amplified GST fragment was cloned into the Gateway pDONR221 plasmid (Methods). 
To ensure that the GST insert was successfully cloned into the donor vector a restriction 
enzyme digest was performed (Figure 3.4). DNA fragments of the expected sizes of 2561 
bp and 2200 bp were identified for the empty pDONR221 control plasmid (Figure 3.4, 
lane 3). For the GST insert vectors, DNA fragments of the expected sizes of 2200 bp and 
1001 were observed, suggesting that the cloning reaction had been successful (Figure 3.4, 
lane 5, 7). The GST fragment was then shuttled into a Gateway expression vector, 
pDEST14. The pDEST14 vector does not contain an epitope tag, so only the GST clone 
will be expressed.   
3.2.2 GST Control Expression and Purification 
The GST control fragment was expressed and purified using the procedure 
described above (3.11). To confirm the identity and purity of the GST control fragment, 
the purified sample was run on an SDS-PAGE gel and examined by a western blot 
(Figure 3.5). The band for the GST protein samples was close to the expected size of 25.5 
kDa (Figure 3.5, lane 1). The GST sample was not observed by a Ponceau-stained gel 
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suggesting that the sample is of low concentration. 
3.3 Validating RC Nuclear Extracts and Nuclear TFs 
In preparation for the proposed immunoprecipitation assay, I examined the 
protein content of the RC lymphoma cell line nuclear extracts to ensure the quality of the 
nuclear extraction process. A western blot was performed probed using antibodies against 
different transcription factors to check to see if they are expressed in the RC nuclear 
extracts. The membrane was probed with RBBP5, a nuclear protein that is highly 
expressed in mammalian cells (Garapaty et al., 2009), to ensure that the nuclear proteins 
were extracted and that there was no nuclear contamination in the cytosolic fraction 
(Figure 3.6). There was no RBBP5 expression in the cytosolic fraction indicating no 
nuclear contamination. (Figure 3.6, lane 1). RBBP5 was highly expressed (Figure 3.6, 
lane 2). Also, our preliminary hTF experiments demonstrated that DNMT3A was 
recruited by IRF- and ETS-family proteins. Using published gene expression data, I 
identified several IRF- and ETS-family TFs likely to be present in the RC nuclear 
extracts. By western blot we tested for the presence of IRF3, IRF7, and the ETS-family 
protein ELK1 in the RC cell extracts. RBBP5, IRF3, and IRF7 were expressed strongly 
while ELK1 was expressed weakly. As a control, we also tested for the presence of 
DNMT3A. These western blot experiments confirmed the presence of key proteins in our 
nuclear extract, and also demonstrated that the selected antibodies worked well in 
western blot assays.  
3.4 GST-Tagged DNMT3A ADD Domain Pulldown 
I reasoned that due to the western blot results and hTF array results, DNMT3A 
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protein likely interacted with the IRF3 protein, and began by testing for an interaction 
between DNMT3A/B ADD domains and this IRF protein. The GST-tagged purified 
DNMT3A ADD domain protein was incubated with glutathione magnetic beads and RC 
nuclear extracts in order to capture potential TF-COF interactions. After performing the 
pulldown assay, the precipitated proteins were analyzed with a Ponceau-stain gel and a 
western blot (Figure 3.10, Figure 3.11). Due to the high TF-COF interaction z-score seen 
on the hTF array, the transcription factor IRF3 was probed for to confirm the result seen 
on the hTF array as well as to see if the ADD domain mediates the DNMT3A-IRF3 
interaction. A high z-score means that DNMT3A is strongly recruited by IRF3. A band 
for IRF3 was seen in the input lane which was expected (Figure 3.11, lane 2). There was 
a band with similar intensity to the input lane in the unbound lysate GST-tagged 
DNMT3A ADD domain lane (Figure 3.11, lane 3). This indicates that most if not all 
IRF3 did not bind to the ADD domain. Ultimately no band was seen in the GST-tagged 
DNMT3A ADD domain elution lane (Figure 3.11, lane 5). No band for IRF3 was 
detected in the wash lane either (Figure 3.11, lane 4). Therefore, due to the fact that there 
was no band for IRF3 in the elution lane, we cannot say that the ADD domain mediates 
the TF-COF interaction between DNMT3A and IRF3. As well as being recruited by 
IRF3, the hTF array indicated that DNMT3A is strongly recruited by ELK1. However, 
since ELK1 was weakly expressed in RC cells, ELK1 was not probed for on the 
membrane as it would be difficult to detect ELK1 in the pulldown assay. 
3.5 Pulldown Using Native DNMT3A Antibody 
 The TF IRF7 is known to interact with DNMT3A (Hervouet et al., 2018). The 
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hTF results also indicated that DNMT3A recruits IRF7. Therefore, I examined the 
interaction of DNMT3A with IRF7 from RC cells. A pulldown assay was performed 
using a native DNMT3A antibody and RC nuclear extracts in order to see if DNMT3A as 
a whole interacts with IRF7. The precipitated proteins were analyzed with a Ponceau-
stain gel and a western blot and (Figure 3.12) (Figure 3.13). Although it was confirmed 
previously that IRF7 is expressed in RC cells and that the Ponceau stain showed many 
protein bands in the input lane, there was no band for IRF7 in the input lane (Figure 3.13, 
lane 1). There was no band detected in the unbound nuclear extract DNMT3A lane 
indicating that all of the IRF7 protein in the extract bound to DNMT3A (Figure 3.13, lane 
2). There was also no band detected in the unbound nuclear extract lane mouse IgG lane 
indicating that all of the IRF7 antibody bound to the mouse IgG (Figure 3.13, lane 6). 
There was a band detected for IRF7 in the DNMT3A elution lane and mouse IgG control 
lane (Figure 3.13, lane 5, 9). This indicates that there is high non-specific binding. Based 
on the result of this experiment, it cannot be concluded that IRF7 interacts with native 
DNMT3A due to no band being visible for IRF7 in the input lane as well as a band being 






Figure 3.1 Confirmation of the DNMT3A/B ADD domain BP reaction. A restriction 
enzyme digest of pDONR221 containing the ADD domain insert of both GST-tagged 
DNMT3A and DNMT3B was performed and ran on a 1% agarose gel. Empty 
pDONR221 was run as a control. The restriction enzymes EcoRV and ApaI were used. 
Boxes indicate correct band sizes. p221 (pDONR221); D3A-ADD (DNMT3A ADD 





Figure 3.2 Expressed and purified GST-tagged DNMT3A and DNMT3B ADD 
domains. A western blot was performed on the GST-tagged DNMT3A and DNMT3B 
ADD domains to verify they were expressed and purified. The membrane was probed 
with anti-GST. As indicated by the arrow, the expected size of 43.6 kDa for DNMT3A 
was observed on the imaged blot as well as the Ponceau stain. The membrane was 









Figure 3.3 GST amplified from pDEST15. The expression plasmid pDEST15 was used 
as the template and primers were designed to amplify GST out of pDEST15. The PCR 
reaction was electrophoresed on a 1.2% agarose gel. The GST fragment was the expected 





Figure 3.4 Confirmation of the GST cloning reaction into pDONR221. A restriction 
enzyme digest of empty pDONR221 and pDONR221 containing the GST control insert 
was performed and ran on a 1% agarose gel. Empty pDONR221 and digested empty 
pDONR221 were run as controls. Both empty pDONR221 and pDONR221 and GST 
were digested with the restriction enzymes EcoRV and BbsI. Two replicates of the 
pDONR221 plasmid containing the GST control were run. Boxes indicate correct band 









Figure 3.5 Expressed and purified GST fragment. A western blot was performed on 
the PCR amplified GST fragment. The membrane was probed with anti-GST. As 
indicated by the arrow, the expected size of 25.5 kDa for the GST fragment was observed 
on the imaged blot. The membrane was exposed for two minutes. The Ponceau stain was 




Figure 3.6 RBBP5 expression in the nuclear and cytosolic fractions of RC cells. A 
western blot was performed on the cytosolic and nuclear proteins obtained from the 
nuclear extraction of the RC cell line. The membrane was probed with an antibody 
specific to RBBP5. RBBP5 was not detected at all in the CF (cytosolic fraction) lane 
indicating no nuclear contamination. RBBP5 was detected strongly in the NE (nuclear 





Figure 3.7 DNMT3A expression in the nuclear fraction of RC cells. A western blot 
was performed on the nuclear proteins obtained from the nuclear extraction of the RC cell 
line. The membrane was probed with an antibody specific to DNMT3A. DNMT3A was 







Figure 3.8 IRF3 and IRF7 expression in the nuclear fraction of RC cells. A western 
blot was performed on the nuclear proteins obtained from the nuclear extraction of the 
RC cell line. One membrane was probed with an antibody specific to IRF3. Another 
membrane was probed with an antibody specific to IRF7. Both IRF3 and IRF7 were 







Figure 3.9 ELK1 expression in the nuclear fraction of RC cells. A western blot was 
performed on the nuclear proteins obtained from the nuclear extraction of the RC cell 
line. The membrane was probed with an antibody specific to ELK1. ELK1 was weakly 









Figure 3.10 Ponceau stain of pulldown performed with GST-tagged DNMT3A ADD 
domain and RC nuclear extracts. The input was 10% of the total amount of protein 
used for immunoprecipitation. After an overnight incubation, GST protein and RC extract 
were separated from the unbound nuclear extract with a magnet. BSA was highly 
concentrated in both unbound nuclear extract lanes. Incubated GST protein and RC 
extract was washed with HBS and Tween for 30 seconds. Second wash was kept for 
analysis. Unbound nuclear extract (UNE); GST-tagged DNMT3A ADD domain 




Figure 3.11 In vitro association of IRF3 with the ADD domain of DNMT3a. The 
GST-tagged DNMT3A ADD domain was incubated with RC nuclear extracts. 
Immunoprecipitation analysis of IRF3 done using an antibody against IRF3. The input 
was 10% of the total amount of protein used for immunoprecipitation. After an overnight 
incubation, GST protein and RC extract were separated from the unbound nuclear extract 
with a magnet. Incubated GST protein and RC extract was washed with HBS and Tween 
for 30 seconds. Second wash was kept for analysis. Unbound Nuclear Lysate (UNE); 







Figure 3.12 Ponceau stain of pulldown performed with native DNMT3A antibody 
and RC nuclear lysates. 12 μg of native DNMT3A antibody was incubated with RC 
nuclear extracts. The input was 10% of the total amount of protein used for 
immunoprecipitation. After a 30-minute incubation, native DNMT3A antibody and RC 
extract was separated from the unbound nuclear extract with a magnet. BSA was highly 
concentrated in both unbound nuclear extract lanes. Incubated native DNMT3A antibody 
and RC extract was washed with HBS and Tween for 1 minute and 30 seconds. First and 
second wash was kept for analysis. Unbound nuclear lysate (UNE); First wash (W1); 





Figure 3.13 In vitro association of IRF3 with native DNMT3a. 12 μg of native 
DNMT3A antibody was incubated with RC nuclear extracts. Immunoprecipitation 
analysis of IRF7 done using an antibody against IRF7. The input was 10% of the total 
amount of protein used for immunoprecipitation. After a 30-minute incubation, native 
DNMT3A antibody and RC extract were separated from the unbound nuclear extract with 
a magnet. Incubated native DNMT3A antibody and RC extract was washed with HBS 
and Tween for 1 minute and 30 seconds. First and second wash was kept for analysis. 





CHAPTER 4: Discussion 
 
The hTF array approach for profiling COF recruitment from nuclear extracts 
allows us to determine which TFs are capable of recruiting a COF of interest without 
having to directly profile the binding of each TF. We can then take advantage of this to 
investigate multiple COF-TF complexes across different cell states or different cell types. 
Through the use of the hTF array we were able to investigate TF-COF complexes in 
cancer cells, such as B-cell lymphomas This provided insight as to which TF-COF 
complexes are involved in establishing and/or maintaining these aberrant epigenetic 
states. The main purpose of this current study was to validate a recent experiment 
performed on the hTF array using a GST-tagged DNMT3A ADD domain pulldown with 
RC nuclear extracts. As well as validating the hTF result, I also attempted to characterize 
which specific part of DNMT3A was responsible for mediating binding.  
The initial aim of this study was to clone the ADD domain of DNMT3A and 
DNMT3B and into pDONR221 and pDEST15 plasmids and then express them in 
bacteria. As seen in the results, I was able to successfully clone, express, and purify the 
ADD domain of DNMT3A and DNMT3B. Using cloned and purified domains from 
COFs instead of the entire COF itself can allow us to find COF-TF interactions and 
identify which domains mediate these interactions. This type of analysis cannot be 
performed using the entire protein.  
The next aim of the study involved finding out whether certain TFs were 
expressed in the RC B-cell lymphoma cell line. The hTF results indicated that IRF3, 
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IRF7, and ELK1 are potential interactors with DNMT3A. It was confirmed that the 
transcription factors IRF3, IRF7, and ELK1 were expressed in RC cells, albeit at different 
intensities. IRF3, and IRF7 were expressed strongly (Figure 3.8). ELK1 was expressed 
weakly (Figure 3.9). I also needed to confirm that RC cells express DNMT3A because 
the bait protein in the pulldown assay will contain the ADD domain of DNMT3A. It was 
determined that DNMT3A was moderately expressed in RC cells (Figure 3.7). This could 
provide a potential problem as it is ideal to have both TF and COF highly expressed in 
the cell type that is being investigated. The yield from immunoprecipitation assays is 
usually low so it will be difficult to detect proteins that are weakly expressed in RC cells. 
Now that the cloned and purified GST-tagged ADD domain was obtained as well 
as the extracted nuclear proteins from the RC cells, a pulldown experiment could be 
performed by incubating the GST-tagged ADD domain of DNMT3A with the RC nuclear 
extracts. After performing the pulldown experiment, it was concluded that there was no 
interaction seen between IRF3 and the ADD domain of DNMT3A due to the fact that 
there was no band in the elution lane (Figure 3.1.2). There are many reasons why this 
assay failed to show a DNMT3A ADD domain and IRF3 interaction. One reason is that 
pulldown conditions may not have been ideal. The makeup of the binding buffer may not 
have been conducive for TF-COF interactions. The concentration of BSA in the binding 
buffer may have been too high. Having too concentrated BSA, which serves as a blocking 
agent, can block potential TF-COF interactions. I would decrease the concentration of 
BSA by half as the Ponceau stain showed two large bands for BSA (Figure 3.1.1). Also, 
certain TF-COF interactions may be better stabilized in different salt concentrations. For 
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this assay, 100 mM NaCl was used but the salt concentration could potentially have to be 
raised or lowered in order to visualize these TF-COF interactions. Also, even though 
IRF3 was shown to strongly recruit DNMT3A on the hTF array, all the TFs in the IRF 
family have similar binding sites so a different member of the IRF family may have been 
the one that recruited DNMT3A. For example, IRF7 or IRF4 may interact with the ADD 
domain but not IRF3. IRF3 could also bind to a different domain on DNMT3A or finally, 
DNMT3A may be recruited to DNA in a different way that does not require recruitment 
to a TF.  
Due to being unable to map TF binding specifically to the ADD domain of 
DNMT3A, the final aim of the study was to see if the TF IRF7, which has been shown to 
interact with DNMT3A, interacts with the native DNMT3A in the RC cell line. I could 
not conclude that IRF7 interacts with DNMT3A as a whole due to the fact that there was 
no band for IRF7 expression in the input lane (Figure 3.1.4). Also, although there was a 
band for IRF7 in the DNMT3A elution lane, there was also a band for IRF7 in the mouse 
IgG control lane meaning that IRF7 is not specific to DNMT3A. Even though I was not 
able to make any definitive conclusions in this experiment, the results seemed somewhat 
promising and with further optimization, the experiment could yield positive results. To 
improve upon this experiment I would decrease the incubation time of both antibodies in 






CHAPTER 5: Future Directions 
 
As we had limited success with the immunoprecipitation assays to validate 
DNMT3A-IRF interactions, an initial step would be to optimize the protocols for both the 
GST-tagged domain and native protein assays as described previously. To better 
understand the possible interactions between the DNMT3 ADD domains and TFs, it 
would be useful to perform a hTF array experiment with the GST-tagged DNMT3B ADD 
domain and incubating with the RC nuclear extracts in order to see if the ADD domain 
mediates particular TF interactions. Based on this more focused ADD domain-based 
profiling, I would attempt to validate the results from that hTF array with a pulldown as 
described previously.  
There may be another domain of DNMT3A that mediates TF-COF so I could 
clone and express another domain to use in pulldown assays. I would also examine hTF 
data and investigate other cofactors that are implicated in B-cell lymphomas. For 
instance, RBBP5 was shown to recruit many TFs. I would therefore clone a domain from 
RBBP5 and perform a pulldown assay with B-cell nuclear proteins. I would also perform 
a pulldown with different subtypes of B-cell lymphoma cell types such as SU-DHL-4 or 
KARPAS-422 to explore if different cell types have differences in binding.  
The immunoprecipitation assay used here can only map one TF-COF interaction 
at a time. Therefore, another potential direction would be to perform the pulldown assays 
as previously described but after the incubation period, perform mass spectrometry on the 
bead-protein mixture. This will show us all the TFs that are interacting with a particular 
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COF. Finally, if the ADD domain or a domain of any cofactor or instance was shown to 
mediate TF interactions, I would then construct a reporter gene assay to determine if the 
domain had any transcriptional function in the cell.  
Being able to identify a domain of a cofactor, especially an epigenetic modifier 
like DNMT3A that mediates TF-COF interactions will allow us to further investigate that 
domain to see if it causes an aberrant epigenetic state. 
In all, the hTF array can allow us to map multiple TF-COF complexes across 
different cell states and different cell types. We may be able to identify if changes in 
these complexes are giving rise to changes from a normal epigenome to a cancerous 
epigenome. Ultimately, we may be able to identify epigenetic modifiers that could be 
great targets for therapies.
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